Lancet Neurology

Article	Citations
The East Asian Parkinson Disease Genomics Consortium	4306
Implications of the KIWE trial for low-income and lower-middle-income countries	965
Multidisciplinary care for amyotrophic lateral sclerosis	633
Lessons and future directions for GBA1-targeting therapies	632
New therapies for Pompe disease: are we closer to a cure?	602
Dementia diagnosis in the anti-amyloid era	602
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	482
Traumatic brain injury research: homogenising heterogeneity	463
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	420
Correction to Lancet Neurol 2024; 23: 168–77	381
Correction to Lancet Neurol 2022; 21: 42–52	378
Correction to Lancet Neurol 2021; 20: 448–59	373
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	368
The predictive value and clinical use of the neurological pupillary index – Authors' reply	355
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	347
The relevance of social and commercial determinants for neurological health	326
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	274
Global burden of stroke: dynamic estimates to inform action	268
RAB32 mutation in Parkinson's disease	259
Pseudomedicine for sports concussions in the USA	245
Increasing diversity in dementia research	244
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	244
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	241
Anti-CD19 CAR T cells for refractory myasthenia gravis	235
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	231

Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	221
A biological classification of Huntington's disease: the Integrated Staging System	201
Management of atherosclerotic extracranial carotid artery stenosis	190
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	189
A chilly tale of dementia	188
A sensitive portrayal of a controversial condition	185
Trials in intracerebral haemorrhage: a path to success?	185
A study in healing the wounds of trauma	178
Beyond the modular brain	173
Epilepsy syndromes: an essential piece of the puzzle	173
Elia M Pestana Knight	170
Delving into the human mind	167
Albert Kwaku Akpalu	161
A blood test for Alzheimer's disease: a step forward	157
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	153
Surrogate endpoints for progressive multifocal leukoencephalopathy	148
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	148
Safe laboratory management of prions and proteopathic seeds	144
Diana Cejas	143
Considering the neurological health needs of LGBTQIA people	141
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	139
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	139
Diversity and inclusion in neurosurgery	139
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study	137
Movement disorders research in 2021: cracking the paradigm	137
Parkinson's disease is a recognisable and useful diagnostic entity	131
Gene therapy for X-linked myotubular myopathy: the challenges	127
Correction to Lancet Neurol 2022; 21: 284–94	124
Correction to Lancet Neurol 2023; 22: 812–25	123
Aspiring to restore arm and hand function after stroke	123
Amyotrophic lateral sclerosis from genotoxins alone?	121
A nasal CGRP receptor antagonist for acute migraine therapy	121
Development of treatments for Down syndrome	118
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	116
From stroke awareness to stroke action awareness	114
The prescription of valproate: risk of harm	113
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	106
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	104
Encephalitis awareness: our ambitious global endeavour	103
Better buildings for elderly people to thrive	102
Poldi Wilbrink	102
New results for risdiplam in spinal muscular atrophy	98
Expansion of stenting indications in the USA	98
Correction to Lancet Neurol 2021; 20: 687–89	97
Neurological infections in 2023: surveillance and prevention	95
Jessica Ailani	91
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	90
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	89
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	88
Spontaneous intracranial hypotension: searching for the CSF leak	87

α-synuclein seed amplification and its uses in Parkinson's disease	87
A proposal for equity neuroscience	87
Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies	87
Brain health in the Philippines	86
Multiple sclerosis in 2022: old players, new insights	86
Correction to Lancet Neurol 2024; 23: 110–22	85
Correction to Lancet Neurol 2022; 21: 620–31	85
In search of Charcot's second sight	84
Detection of ionising radiation by the CNS: a case report	83
Redefining use of MRI for patients with multiple sclerosis	82
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial	81
The International Brain Initiative: enabling collaborative science	77
Cognitive function in people with functional seizures	77
Responsible innovation in neurology	77
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	77
Changing multiple-sclerosis-induced thoughts and behaviours	76
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	76
Major advances in Parkinson's disease over the past two decades and future research directions	74
Supporting young carers across neurological disorders	74
Learning to be an adult with a disability	74
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	73
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial	73
Bastiaan Bloem: power against Parkinson's disease	72
Sleeping matters	71
Brains are neither pink nor blue but fifty shades of grey matter	71
Living with dementia: seeing the world and adapting to it	70
Eugenia Martínez	70
Blocking inhibitors of axon growth after spinal cord injury	69
Headache research in 2023: advancing therapy and technology	69
Correction to Lancet Neurol 2024; 23: 961–62	68
Monitoring brainwaves while gallery visitors view artworks	68
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	66
Your After-Visit Summary—May 29, 2042	66
Andrea Schneider	66
Pragmatic solutions for the global burden of stroke	66
Highlights in traumatic brain injury research in 2024	66
ELEVATEd hope for patients after migraine treatment failure	66
A call for optimal oral care in patients with ALS	65
Improving thrombolysis efficiency for acute ischaemic stroke	64
Epilepsy research in 2022: clinical advances	63
Detection of awareness after brain injury: time for change	62
Expanding the spectrum of type 1 IFN neuroinflammation	60
Neuroprotection in acute ischaemic stroke: reasons for optimism?	60
Thrombolysis before endovascular treatment of tandem lesions	58
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	58
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	58
The global challenge of hypertension	58
Consciousness contextualised	57
Diagnosis and treatment of orthostatic hypotension	55
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	55
The AfrAbia+plus Parkinson's Disease Genomic Consortium	53
Correction to Lancet Neurol 2024; 23: 344–81	53
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	51
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	51
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	51
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	51
Targeting auto-antibodies for CIDP: hope and questions	51
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	51
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	50
Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-con	49
The torment of needing to know for sure	48
The cultural history of dementia	47
Biomedical research must change as the climate does	47
Geoffrey Manley: TBI guy	46
Neurosurgical lesioning for Tourette syndrome – Authors' reply	46
The bases of remembrance	46
Charles Sherrington's apparatus	46
A brain design for life	45
Thank you to The Lancet Neurology's peer reviewers in 2023	45
Early atrial fibrillation rhythm control after stroke	45
Major advances in sleep neurology: 2002–22	45
Laquinimod, Huntington's disease, and disease modification	44
Carlayne Jackson: leading the American Academy of Neurology	44
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	43
Sleep research in 2023: beyond the bare necessities	43
Angela Dos Santos	42
Digital mobility measures to predict Parkinson's disease	42
Changing the landscape of neurological education	41
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	41
A decisive year for the neurological community	41

Therapies for myasthenia gravis: FcRn inhibition and beyond	40
Correction to Lancet Neurol 2021; 20: 1012–16	39
Advances in amyotrophic lateral sclerosis research in 2022	39
Correction to Lancet Neurol 2024; 23: 465–76	39
Further support for rituximab in relapsing multiple sclerosis	37
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	37
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	35
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	35
Frailty and outcome after traumatic brain injury	35
NfL is ready for translation into paediatrics	35
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	35
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	34
No area of stroke research should be left behind	34
Improving epilepsy diagnosis across the lifespan: approaches and innovations	33
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	32
The complex pathway between amyloid β and cognition: implications for therapy	32
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	31
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	31
For a dementia diagnosis, clinical acumen must precede biomarkers	31
Helping to bring the crisis home	30
Teshamae Monteith	30
Sleep matters in anti-LGI1 encephalitis	29
Globally advancing neurological education in headache	29
Correction to Lancet Neurol 2021; 20: 615–26	28
Blue as an orange	28
Correction to Lancet Neurol 2024; 23: 344–81	28
Correction to Lancet Neurol 2021; 20: 739–52	28
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	27
Correction to Lancet Neurol 2018; 17: 954–76	27
Friston's theory of everything	27
Correction to Lancet Neurol 2023; 22: 209–17	27
Neuroscience in the 21st century: circuits, computation, and behaviour	27
Revisiting levodopa for advanced Parkinson's disease	26
Time to get serious about the Global Action Plan on dementia	26
The prescription of valproate: risk of harm	26
Global burden of meningitis and implications for strategy	26
Nitrous oxide and its neurological harms	25
Neuroscience research in 2024: advances in blood biomarkers and brain omics	25
Maria Trojano: advocate for real-world multiple sclerosis studies	25
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	24
Off-label use of aducanumab for cerebral amyloid angiopathy	24
Nanna Brix Finnerup: integrity and openness to alternatives	24
Abandon the NAC in α-synuclein	24
RAB32 mutation in Parkinson's disease	24
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	24
Advances in diagnosis, classification, and management of pain in Parkinson's disease	24
Heart health meets cognitive health: evidence on the role of blood pressure	24
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	23
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	23
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	23
A new definition of brain health	23
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	22
CGRP-targeted drugs for migraine: still many uncertainties	22
Treatment of acute subdural haematoma – Authors' reply	22
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis	22
Amyotrophic lateral sclerosis: a lesson in translation	22
Lightning progress in child neurology in the past 20 years	21
Dancing with paper	21
Cerebral amyloid angiopathy criteria: the next generation	20
Addressing neurological burden in the Americas	20
With thanks to our peer reviewers in 2022	20
Vittorio Marchi's staining	20
Treatment of asymptomatic carotid stenosis in SPACE-2	20
The hidden unity of the mind	20
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	19
Fetal exposure to antiseizure medications: reassurance and concerns	19
Correction to Lancet Neurol 2021; 20: 703–04	19
Innovation in the prevention of neurological diseases	19
Time to end the stigma of epilepsy	19
Transforming amyotrophic lateral sclerosis into a liveable disease	19
A neurotransmitter with a fascinating story	19
Neurology cannot be embedded in non-communicable disease agendas	18
Carotid revascularisation for carotid stenosis	18
CGRP blockade and cluster headache: another step forward	18
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	18
A disease-specific therapy in facioscapulohumeral muscular dystrophy	18
The neuropsychiatry of Parkinson's disease: advances and challenges	17
Differential diagnosis of suspected multiple sclerosis: global health considerations	17
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	17
Chronic effects of inflammation on tauopathies	17
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	17
A genetic basis for the severity of multiple sclerosis	17
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	17
Carpal tunnel syndrome: updated evidence and new questions	17
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	17
Turin as a neuroscience cradle	16
Antibiotic neuromuscular junction myasthenic mimetics	16
Multiple sclerosis meets systems immunology	16
Rigmor Højland Jensen: the headache warrior	15
Alzheimer's disease: a history revisited	15
Neuropsychiatric research in 2023: mechanisms of stress and therapies	15
Kathleen Friel	15
Changing views of disability	15
Targeting C9orf72 in people with ALS	15
A deep scream into the future	15